American Society of Hirudotherapy

Leech Saliva Extract (LSE) Nano-Liposomal Anti-VEGFA

Nano-liposomal medicinal leech saliva extract (46.23 nm) downregulates VEGFA + induces apoptosis in MCF-7 breast-cancer cells — Shakouri 2021.

Preclinical / mechanisticLast updated: 2026-05-28 · Reviewed by ASH Editorial Board

Mechanistic Evidence Box

Preclinical / mechanistic
Page type
Compound profile
Evidence type
Nano-liposomal medicinal leech saliva extract (46.23 nm) downregulates VEGFA + induces apoptosis in MCF-7 breast-cancer cells — Shakouri 2021.
Evidence level
In vitro
Drug vs leech
Leech-derived crude extract

Clinical translation limit

LSE nano-liposomal anti-VEGFA activity in MCF-7 cells does NOT establish clinical efficacy. Breast cancer is not an FDA-cleared K040187 indication; clinical translation requires animal pharmacokinetic / immunogenicity / efficacy studies and randomised human trials.

Molecular Profile

Category
Other
Evidence tier
Preclinical
Source species
Hirudo medicinalis (saliva extract)
Discovered
2021 · Shakouri A et al.
Leech Saliva Extract (LSE) Nano-Liposomal Anti-VEGFA molecular structure

Biological Targets

  • VEGFA gene expression; HIF1α; p53 (cancer cell)

Key Citations

  1. Shakouri A et al. (2021), Bioimpacts · PMID 35411300

External Resources

    Related Other Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.